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Re-exposure to beta cell autoantigens in pancreatic allograft recipients with pre-existing 
beta cell autoantibodies. 
 
Abstract: 
 
Re-exposure to beta cell autoantigens and its relevance in the presence of  donor specific 
antibodies (DSA) in pancreas allograft recipients is not well known.  
Thirty-three patients requiring a pancreas transplant were enrolled in an IRB approved study. 
They underwent prospective monitoring for DSA and beta cell autoantibody (BCAA) levels to  
GAD65, Insulinoma-associated-antigen 2(IA-2), insulin (micro-IAA [mIAA]), and islet-specific 
zinc-transporter isoform-8 (ZnT8).  
Twenty-five (75.7%) had pre transplant BCAA. Twenty had a single antibody (mIAA n=15, 
GAD65 n=5); five had two or more BCAA (GAD65+mIAA n=2, GAD65+mIAA+IA-2 n=2, 
GA65+mIAA+IA-2+ZnT8=1).No changes in GAD65 (p>0.29), IA-2 (>0.16), and ZnT8 
(p>0.07) were observed between pre-transplant and post-transplant at 6, or 12-months. A 
decrease in mIAA from pre to post 6-months (p<0.0001), 12- months (p<0.0001), and from post-
6 to post 12-months (p 0.0002) was seen. No new BCAA was observed at 1-year. Seven (21.0%) 
developed denovo-DSA. The incidence of DSA was 24% in patients with BCAA vs. 25% in 
patients without BCAA (p=0.69). Pancreatic allograft function of patients with vs. without 
BCAA, and with and without BCAA+DSA was comparable until last follow-up (3yrs).Re-
exposure to beta cell autoantigens by pancreas transplant may not lead to increased levels or 
development of new BCAA or pancreas allograft dysfunction.  
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Introduction:  
 
Type 1 diabetes mellitus (T1DM) is a T cell mediated autoimmune disease in which the β cells 
of the islets of Langerhans are selectively destroyed (1). Autoantibodies to beta cell antigens are 
present at, and required for the, the diagnosis of T1D (2, 3). The timing and number of 
autoantibodies precedes and are predictive of clinical onset of disease (4). The exact mechanisms 
involved with the interactions of beta cell autoantigens and cells of the innate (macrophages and 
dendritic cells) and adaptive (T and B cells) regarding the initiation and progression of beta cell 
destruction are not clear (5-7). Beta cell autoantigens are processed by macrophages, dendritic 
cells, or B cells in the pancreatic islets and presented to auto reactive CD4+ T cells in the 
peripheral lymphoid system. These auto reactive CD4+ T cells are activated and secrete 
cytokines, which can activate β cell–specific cytotoxic CD8+ T cells. The activated T cells are 
recruited to the pancreatic islets and produce cytokines, which further activate macrophages and 
other T cells, contributing to the destruction of β cells(8). The first diabetes autoantibodies that 
were identified were islet cell autoantibodies (ICAs), which actually represent autoimmunity to 
several different antigens (1, 2). More recently, autoantibodies specific to single tissue antigens, 
termed biochemical autoantibodies, have been identified (9-14). These include antibodies to 
GAD 65(GAD65); the antibody to an Insulinoma associated Antigen-2 (ICA512), antibodies to 
insulin (IAA), and antibodies to islet-specific zinc transporter isoform 8 (ZnT8). In order to 
improve diabetes metabolic control, some patients receive a pancreas transplant or an islet cell 
transplant. In many cases this is done in conjunction with a kidney transplant due to diabetes-
related renal failure. In most cases, this results in improved metabolic control and in some 
instances insulin independence. Yet even though patients are receiving powerful immune 
suppression for their transplants, some patients reject their pancreas or islet cell transplants while 
maintaining their renal graft. The rejection of their pancreas/islet cells appears to due to a 
combination of alloimmunity and recurrent autoimmunity. (5-7). Development or reemergence 
of autoantibodies to islet beta cells (BCAA) and denovo HLA donor specific alloantibodies 
(DSA) are considered to be important prognostic markers (15). We carried out the present study 
to analyze the trend of diabetes autoantibodies and HLA DSA antibodies in successful whole 
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organ pancreatic transplant recipients with our practice of induction and maintenance 
immunosuppression. Here we present our findings.  
 
Methods: 
 
Study Subjects: Thirty-three patients with previously diagnosed Type 1 diabetes with technically 
successful pancreas transplant (13 pancreas-alone [PTA], 20 with a kidney [SPK] were enrolled 
in a IRB approved clinical study. Serum samples were collected prospectively immediately 
before transplantation at 6 and 12 months and stored frozen until testing in batch analysis. All 
pancreas allografts were implanted with systemic venous and enteric exocrine drainage. 
Induction immunosuppression consisted of rabbit antithymocyte globulin (1 mg/kg x 5) and 
steroid withdrawal with the addition of anti-CD20 for PTA recipients.  Routine maintenance 
immunosuppression included tacrolimus (12 hours trough 6-8ng/ml) and sirolimus (24 hour 
trough 4-6ng/ml) with the addition of mycophenolate mofetil (500 mg bid) for PTA. All subjects 
are alive with a functioning pancreas allograft at three years as assessed by clinical follow-up. 
 
Anti-HLA Antibody Determination: Donor specific antibody specificity (DAS) was analyzed 
using LUMINEX platform solid phase based test systems (LabScreen®, One Lambda Inc., 
Canoga, CA). Microbeads coated with individual purified Class I or Class II HLA antigen are 
incubated with patient serum that has been pretreated with DTT to reduce IgM antibodies. Beads 
are then washed and labeled with R-Phycoerythrin (PE) conjugated goat anti-human IgG. 
Luminex acquisition data is analyzed to determine test pattern reactivity and assign specificity. 
Mean fluorescence intensity (MFI) greater than 2600 for Class I and greater than 3600 for Class 
II is considered positive based on correlation with flow cyotometric crossmatches. Results are 
determined using manufacturer’s Fusion software. 
 
Diabetes-related Autoantibodies: All sera were tested at the Barbara Davis Center Aurora, CO. 
as follows. 
 
GAD65 and IA-2 Autoantibody Standardized Radioassay: GAD65 autoantibody (GADA) and 
IA-2 autoantibody (IA-2A) radioassay were performed with NIDDK harmonized standard 
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methods. The GAD65 cDNA (full length), pThGAD65, was kindly provided by Dr. Åke 
Lernmark and IA-2 cDNA (intracellular domain, a.a. 605 to 979), IA-2ic, by Dr. Ezio 
Bonifacio). Labeled GAD65 and IA-2 proteins were produced by in vitro transcription and 
translation. In vitro translated [35S] GAD65 (20,000 cpm) or [35S] IA-2 (20,000 cpm) in an 
antigen buffer and incubated overnight at 4 0C with 2 µl of patient serum at a final 1:12.5 
dilution. Autoantibody-bound antigen was precipitated with 25 µl of 50% protein A-Sepharose. 
Radioactivity was counted on a TopCount 96-well plate β-counter (Perkin Elmer). The results 
were calculated with an equation from the standard curve in each assay and expressed as DK 
units/ml. 
 
Insulin autoantibody assay (mIAA): Insulin autoantibody (IAA) was measured by a micro-IAA 
assay (mIAA). Briefly, 125-I labeled human insulin (Perkin Elmer) was incubated with patient 
serum with and without cold human insulin and immune complex was precipitated with protein 
A and G Sepharose. The assay was performed on a 96-well filtration plate and radioactivity was 
counted on a Topcount 96-well plate beta counter. An index was calculated upon delta cpm 
between wells without and with cold insulin, with a positivity criterion of 0.010. 
 
ZnT8 Autoantibody Radioassay: ZnT8 autoantibody (ZnT8A) was performed with a 
radioimmunoassay. The ZnT8 cDNA, ZnT8-RW dimmer (JH5.2), was kindly provided by Dr. 
John Hutton. The ZnT8 protein was produced by in vitro transcription and translation (Promega 
TNT kit) and labeled with [35S] methionine (Perkin Elmer). Labeled [35S] ZnT8 (20,000 cpm) 
was mixed and incubated overnight at 4 0C with patient serum at a final 1:25 dilution. 
Autoantibody-bound antigen was precipitated with 25 µl of 50% protein A-Sepharose. 
Radioactivity was counted on a TopCount 96-well plate β-counter (Perkin Elmer). The results 
are expressed as index (index = (sample CPM – negative control CPM)/ (positive control CPM – 
negative control CPM).   
 
Statistical Analysis: 
Statistical analysis used Wilcoxon signed rank tests. A p value of <0.05 was considered 
significant.  
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Results:  
 
The majority of patients were Caucasian (88%) and male (51%) with median age of 45 years and 
mean BMI of 25. Median duration of T1DM was 30 years and majority were SPKs. Median 
follow up on these patients is 36 months. GAD65, mIAA, IA-2 and diabetes autoantibodies were 
assessed in all patients from prospectively collected banked samples taken at baseline, and 6 and 
12 months following transplant. Twenty-five (75.7%) had at least one diabetes auto-antibodies 
pre-transplant. No significant difference in the trough levels of tacrolimus, sirolimus was 
observed at specified time intervals. Fasting blood sugar levels, A1C, C-peptide and serum lipase 
levels were also recorded at specified intervals, no significant differences were observed in the 
patients with or without autoantibodies at the time of last follow up of 36 months 
 
Of those patients with at least one diabetes autoantibody, 20 (80%) had one type of beta cell 
autoantibody (mIAA n=15, GAD65 n=5), whereas 2 or more beta cell autoantibody 
(GAD65+mIAA n=2, GAD65+mIAA+IA-2 n=2, GAD65+mIAA+IA-2+ZnT8=1) were detected 
in 5 (20%) patients.  No statistically significant changes in GAD 65(p>0.29), IA-2 (>0.16), and 
ZnT8 (p>0.07) were observed between pre-transplant and post-transplant antibody levels at 6, 
and 12 months [Table 1], however a significant decrease was noted in mIAA titers from pre to 6 
months post-transplant (p<0.0001), from pre to post 12 months (p<0.0001), and from post 6 to 
post 12 months (p 0.0002). No new formation of beta cell autoantibody was observed at 1 year of 
follow up [Figure 1]. There was no significant difference at 6,12,24 and 36months in pancreas 
allograft function as assessed by clinical parameters of fasting blood sugar levels, A1C, C-
peptide and serum lipase levels in patients with one autoantibody versus two or more 
autoantibodies.   
 
Patients were also assessed for DSA during these times. One patient had pre-transplant DSA 
whereas 7 (21.0%) patients developed de novo DSA at median follow up of 76 days. Incidence 
of DSA was 24% (n=6) in patients with any diabetes autoantibody vs. 25% (n=2) in patients 
without autoantibodies (p=0.69). Seven patients had both class I and class II DSA. Mean peak 
class I DSA-MFI was 3529 (±1456); class II DSA-MFI was 5412 (±2204) whereas cumulative 
DSA MFI (CI + CII) was 8941 (±3660). Figure 2 shows trend of DSA in individual patient. No 
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significant difference was noted in the DSA MFI of patients with or without beta cell 
autoantibodies. No significant difference was noted in the pancreatic allograft function parameter 
of patients with HLA DSA antibodies and autoantibodies vs HLA DSA antibodies without beta 
cell autoantibodies.  All patients are insulin independent with detectable C-peptide levels and 
A1C of 5.4+/- 0.25 at last clinical follow-up of three years.  
 
Discussion: 
 
Type 1 diabetes is an autoimmune disorder leading to loss of pancreatic β-cells and insulin 
secretion, followed by exogenous insulin dependence. Daily insulin administration is required in 
those with T1DM for survival, yet it is not a cure. Those with T1DM continue to suffer 
significant morbidities and a higher mortality than those without T1DM (16). In an attempt to 
improve metabolic control and lessen the side effects of T1DM, some patients undergo whole 
pancreas or islet cell transplantation, but then require powerful immune suppressive medicine to 
maintain the graft. With improved immunosuppression and technical expertise, immediate 
failures of whole pancreas grafts have become less frequent; however chronic pancreatic 
allograft loss remains a concern (17). This chronic pancreatic allograft dysfunction may be 
related to development of HLA DSA or beta cell autoantibodies. Post-transplant DSA 
monitoring is now considered standard of care in pancreas transplantation at most centers. HLA 
DSA may not impact early pancreas allograft but have been reported to impair long-term 
outcomes (18, 19). Similarly, although rare, recurrence of beta cell autoimmunity has been 
reported in whole organ pancreas transplant (20). Our study is unique, as it looks at both the 
HLA donor specific antibodies as well as beta-cell autoantigens responses in whole pancreas 
recipients at defined time intervals. From the islet transplant experience there is growing 
evidence that recurrence of beta cell autoimmunity is a critical contributor to loss of the 
transplanted islets even in the face of potent immune suppression (15). Thus, markers that might 
assist in early identification of recurrent autoimmunity may assist in the choice of suitable 
candidates for islet cell transplantation or alternative immunomodulatory approaches. The 
absence of DSA in PTA recipients who have received rituximab following Thymoglobulin 
induction is a very interesting finding of our study. Along with this, we did not observe early 
recurrence of beta cell autoantibodies and the patients have excellent pancreatic allograft 
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function based upon clinical parameters of normoglycemia, A1C, c-peptide and pancreatic 
enzyme levels.  
 
Recent data from islet cell transplant antibody monitoring by Lorenzo et al shows that presence 
or changes in DSA or Islet cell antibody predicts outcome in type DM1. In their study, the 
incidence of pre-islet cell transplant DSA and islet antibodies was 49% and 44% respectively. In 
66% of these patients an increase in DSA and autoantibodies was detected on the follow up. The 
study also shows reduced islet survival in patients with increasing antibodies with a median time 
to graft loss of 318 days after donor specific antibodies (DSA) increase and 117 days after 
autoantibody increase (15).  We observed that pancreas allograft behaves differently with regards 
to post-transplant beta cell autoantibodies and development of denovo donor specific antibodies 
compared to reported experience with islet transplant. This relatively weaker auto-immunity and 
absence of development of post-transplant donor specific antibodies in PAT with inclusion of 
rituximab as part of induction therapy requires further studies. Dr Pescovitz from our institution 
has previously demonstrated that rituximab partially preserved beta cell function over a period of 
1 year in patients with type T1DM (21).  In our study development of denovo DSA was not 
associated with the pre or post-transplant beta auto-antibody status. Also note that this group of 
patients are on a steroid free maintenance immunosuppression protocol.   
The limitations of our reported data are lack of pancreatic allograft biopsy and relatively shorter 
follow up. Strengths include adequate number of patients with prospective data and to our 
knowledge the only study where DSA and beta cell autoantibodies were concomitantly 
evaluated.  
From our reported data one can conclude that re-exposure to beta-cell autoantigens in pancreatic 
allograft recipients with pre-existing beta cell auto antibodies may not have a significant impact 
on short and medium term whole organ pancreas transplant outcomes. The incidence of denovo 
post-transplant beta cell autoantibodies also appears to be very low. Future studies with large 
number of patients and longer follow up are required to determine long term impact of re 
exposure to beta cell auto antibodies in pancreas transplant recipients.  
Disclosure: 
None related to this manuscript 
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Figure Ligands:  
 
Figure 1:  
mIAA decreased significantly from pre to post1 (p<0.0001), from pre to post2 (p<0.0001), and 
from post1 to post2 (p=0.0002). No statistically significant changes in GAD65 (p>0.29), IA-2 
(p>0.16), or ZnT8 (p>0.07). Note; Figures are Medians. p-value from Wilcoxon signed rank test 
Figure 2:   
HLA DSA monitoring, SPK; simultaneous pancreas and kidney transplant. 
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